Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults

Abstract

Abstract Background In spring 2020, at the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in Europe, we set up an assay system for large-scale testing of virus-specific and neutralising antibodies including their longevity. Methods We analysed the sera of 1655 adult employees for SARS-CoV-2-specific antibodies using the S1 subunit of the spike protein of SARS-CoV-2. Sera containing S1-reactive antibodies were further evaluated for receptor-binding domain (RBD)- and nucleocapsid protein (NCP)-specific antibodies in relation to the neutralisation test (NT) results at three time points over six months. Results We detect immunoglobulin G (IgG) and/or IgA antibodies reactive to the S1 protein in 10.15% ( n = 168) of the participants. In total, 0.97% ( n = 16) are positive for S1-IgG, 0.91% ( n = 15) were S1-IgG- borderline and 8.28% ( n = 137) exhibit only S1-IgA antibodies. Of the 168 S1-reactive sera, 8.33% ( n = 14) have detectable RBD-specific antibodies and 6.55% ( n = 11) NCP-specific antibodies. The latter correlates with NTs (kappa coefficient = 0.8660) but start to decline after 3 months. RBD-specific antibodies correlate most closely with the NT (kappa = 0.9448) and only these antibodies are stable for up to six months. All participants with virus-neutralising antibodies report symptoms, of which anosmia and/or dysgeusia correlate most closely with the detection of virus-neutralising antibodies. Conclusions RBD-specific antibodies are most reliably detected post-infection, independent of the number/severity of symptoms, and correlate with neutralising antibodies at least for six months. They thus qualify best for large-scale seroepidemiological evaluation of both antibody reactivity and virus neutralisation.

Topics & Concepts